Regulator of G protein signaling 19 (RGS19)

Regulator of G protein signaling 19 (RGS19), also known as GAIP, is a member of the RZ family of RGS proteins in humans encoded by the RGS19 gene[1][4]. RGS19 functions as a GTPase-activating protein (GAP) for Gα subunits of heterotrimeric G proteins, accelerating the hydrolysis of GTP to GDP and thereby terminating GPCR signaling, especially for Galpha i, Galpha q, and Galpha o pathways[1][4][5]. Through negative regulation of GPCR signaling, RGS19 modulates various cellular processes, including cardiovascular development, Wnt/beta-catenin signaling, opioid receptor–mediated pain perception, and possibly Ras-related tumor suppression[3][4][5][6]. It acts both through direct GTPase-accelerating activity and by scaffolding function, assembling protein complexes at membranes with proteins like GIPC[2][7]. RGS19 is of therapeutic interest as a potential drug target for pain management, cardiac conditions, and possibly certain neurological or developmental disorders, though no therapeutic agents directly targeting RGS19 are approved[5].

Other names

GAIP (G alpha interacting protein)RGS19G protein gamma interacting proteinG alpha-interacting protein

Acceleration of GTP hydrolysis by Gα subunits, leading to rapid signal termination. Scaffold/adaptor functions for regulation of protein complexes (e.g., with GPCRs and proteins like GIPC)[2][7]. Negative regulation of downstream effectors of GPCRs, modulating cellular responses.